An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection.

Trial Profile

An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Oseltamivir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Roche
  • Most Recent Events

    • 16 Jun 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 13 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Planned end date changed from 1 Jan 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top